← All trials
NCT04340180
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2022
- First posted
- Apr 9, 2020
- Last posted
- Apr 9, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamOverall official - principal investigator
- University of Alabama, BirminghamReponsible party - principal investigator
- BraccoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.